Lonza Acquires Major US Biologics Site in Vacaville from Roche

• Lonza Group AG has signed an agreement to acquire the Genentech manufacturing facility in Vacaville, US from Roche for USD 1.2 billion in cash.
• The Vacaville site is one of the largest biologics manufacturing facilities in the world by volume.
• The acquisition will increase Lonza’s large-scale biologics manufacturing capacity for mammalian therapies and significantly extend its facility network in the US.
• Lonza plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies.
• Roche products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out as the site transitions to serve alternative customers.
• Lonza has updated its Mid-Term Guidance 2024 – 2028 sales growth range from 11 – 13% CAGR in CER1 to 12 – 15%.

The next important date, Quarterly report, at Lonza Group is on 18.04.2024.

Lonza Group

-0,78 %

+2,39 %

-3,69 %

+14,45 %

-4,74 %

+2,73 %

+94,66 %

+668,97 %

+805,90 %

ISIN:CH0013841017WKN:928619

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max